Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial

What Was Tested

Researchers studied Semaglutide and Dulaglutide in this randomized controlled trial publication.

This head-to-head trial compared semaglutide with dulaglutide in patients with inadequately controlled type 2 diabetes.

Who Took Part

PubMed indexes the participants as middle-aged adults, both men and women.

How the Study Was Run

In design terms this was a randomized, open-label and parallel-group study.

Random assignment meant chance, not the researchers, decided who got Semaglutide and who got the comparison, which limits bias.

Being open-label, the Semaglutide study did not mask who received what.

Groups ran in parallel: each of the participants stayed in one arm throughout.

This was an open-label, parallel-group, phase 3b trial done at 194 hospitals, clinical institutions or private practices in 16 countries.

The primary endpoint was change from baseline in percentage HbA1c; the confirmatory secondary endpoint was change in bodyweight, both at week 40.

This trial is registered with ClinicalTrials.gov, number NCT02648204.

What Was Measured

The subject headings attached to it are Blood Glucose, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Hypoglycemic Agents, Immunoglobulin Fc Fragments, Prognosis and Recombinant Fusion Proteins.

What This Means in Plain Language

The paper is a randomized, open-label and parallel-group study of Semaglutide and Dulaglutide.

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2018 (The lancet. Diabetes & endocrinology), a journal based in England.

More context: the Semaglutide compound page and the Dulaglutide compound page.